The post-market, non-interventional, multicentre, non-randomised, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety and performance of a ChEVAR procedure using the Endurant II/IIs stent graft system (Medtronic) in a real-world setting.
Mercator MedSystems has announced completion of enrolment in the company’s LIMBO-ATX (Lower-limb adventitial infusion of dexamethasone via Bullfrog to reduce occurrence of restenosis after atherectomy-based revascularisation) clinical trial. The primary six-month endpoint data is expected to be available in the second quarter of 2018.
iVascular SLU has announced the initiation of the TINTIN trial, evaluating the combined therapy of Luminor drug-coated balloon (DCB) and iVolution self-expandable stent.
The first patient was treated in the CONTROL hypertension (HTN)-2 clinical study, the Rox Medical’s pivotal study to evaluate the safety and effectiveness of the Rox Coupler used to create an arteriovenous anastomosis in the iliac vessels, in patients with high blood pressure.
Scientists have discovered new information about a molecule which is part of the body’s tissue repair system. This finding could help treat non-healing wounds and injuries, such as diabetic foot.
Venous specialists from around the globe will meet in Melbourne for the much anticipated 2018 World Congress of Phlebology (UIP; 4–8 February, Melbourne, Australia) hosted by the Australasian College of Phlebology.
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration’s (FDA) mini-sentinel assessment, confirming the positive safety and efficacy profile of Xarelto (rivaroxaban) established in the phase III ROCKET AF clinical trials, were published in Pharmacoepidemiology & Drug Safety.
Daiichi Sanyoko has announced the results from their Hokusai-VTE CANCER trial evaluating the direct oral anticoagulant edoxaban for treatment of venous thromboembolism (VTE) in cancer patients.
The European Board of Phlebology has announced that the European Union of Medical Specialists (UEMS) have adopted the European training requirements presented by Jean-Jérôme Guex, president of the newly created Board. The development is the result of a European inter-speciality cooperation as the latest step in a process that started in 2015 with a meeting of the Multidisciplinary Joint Committee in Phlebology at the initiative of several UEMS specialties, including vascular surgery, vascular medicine, dermatology, radiology and general surgery, to elect a board of Phlebology.
Global specialist healthcare company BTG has highlighted the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of pulmonary embolism utilising the company’s EKOS therapy with faster and safer protocols, following the encouraging results of the OPTALYSE PE study.
At the THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA), Esther Kim (Vanderbilt University Medical Center, Nashville, USA) gave a presentation on venous thrombosis in unusual locations, noting that such thromboses tend to occur in younger patients and those with malignancy, and that thrombophilia has a role in most cases and testing for it may be considered.
At THE VEINS at VIVA meeting (10–11 September 2017, Las Vegas, USA), James Froehlich, University of Michigan, Ann Arbor, USA, reviewed guidelines on the management of superficial venous thrombosis (SVT) and emphasised the importance of performing duplex ultrasound in the examination, assessing clot location and extent, considering the risk factors for recurrence and development of deep vein thrombosis (DVT), and discussing with the patient their options on the use of anticoagulants.
The US Centers for Medicare and Medicaid Services (CMS) has posted the 2018 Medicare Physician Fee Schedule (CMS-1678-F) and Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems (CMS-1678-FC). As part of the final rulings, healthcare providers will now be able to bill for VenaSeal utilising the new CPT codes 36482 and 36483. These new codes will take effect on 1 January, 2018.
The first patient has been enrolled in Bolton Medical’s RelayPro US Food and Drug Administration (FDA) Phase II clinical trial.
The first US patient has been treated with VentureMed Group’s Flex scoring catheter. The catheter is used to treat patients with end-stage renal disease.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos